Now Available in Europe, components of the Middle East, Asia, Latin America, and Africa
- Early clients embrace GP workplaces and different community-based healthcare settings
- Latest figures, launched as half of World Diabetes Day, reveal that 1 in 10 adults at the moment are dwelling with diabetes and almost half are undiagnosed1
- The LumiraDx HbA1c take a look at is designed to deal with the rising scientific want for accessible and dependable HbA1c testing in community-based healthcare settings reminiscent of main care, diabetes clinics, rural clinics, retail pharmacy & different decentralised healthcare settings
- The actively managed microfluidic immunoassay is run on the extremely moveable LumiraDx Platform and designed for near-patient testing with linked ends in below seven minutes
- The addition of HbA1c to the quickly rising LumiraDx take a look at menu, allows the consolidation of a number of devices to a single, next-generation level of care Platform; all with a typical workflow
LONDON, Nov. 14, 2022 /PRNewswire/ — LumiraDx Limited (Nasdaq: LMDX), a next-generation level of care diagnostics firm, in the present day introduced the continued industrial enlargement of its HbA1c take a look at, for skilled use throughout a number of care settings. Used alongside the LumiraDx Platform, the take a look at screens identified diabetic sufferers’ HbA1c ranges and likewise serves as an assist in screening and figuring out sufferers who could also be in danger for growing diabetes. Providing ends in below seven minutes from pattern software, the take a look at permits improved effectivity and comfort with on-the-spot diabetes screening and monitoring on the affected person’s facet. The firm introduced the assay had achieved CE marking in late May of this 12 months.
Today’s announcement comes on the heels of in the present day’s World Diabetes Day which known as consideration to latest figures from the IDF Diabetes Atlas that 1 in 10 adults now have diabetes and almost 1 in 2 are undiagnosed. 1 The portability and suppleness of the LumiraDx Platform allows the LumiraDx HbA1c take a look at to deal with the rising scientific want for accessible and dependable HbA1c testing locally healthcare setting to help in faster scientific determination making. The LumiraDx HbA1c take a look at has a reportable vary of 20 – 130 mmol/mol HbA1c (4.0 – 14.0% HbA1c). In an exterior, multi-site scientific examine, the take a look at achieved precision, expressed as imply paired replicate %CV, of ≤2.50% (NGSP) in each capillary and venous entire blood.
David Walton, LumiraDx’s Chief Commercial Officer commented, “As the global prevalence of diabetes is increasing, it’s critical for healthcare professionals to have access to rapid and reliable HbA1c results. The availability of an immediate, lab-comparable HbA1c test has been shown to improve patient outcomes through improved diabetes management. 2,3 In addition, there are a number of well-known comorbidities associated with diabetes. These are supported through our multi-assay testing Platform – including tests for cardiac biomarkers, coagulation, and inflammation- making the LumiraDx Platform an ideal tool for improving patient outcomes within the community healthcare setting.”
Professor Garry John Consultant Clinical Biochemist, Norfolk and Norwich University Hospital, present Secretary of the IFCC Executive Committee of the Scientific Division (SD) and former Chairperson of the IFCC Working Group for the Global Standardisation of HbA1c, Honorary Professor, Norwich Medical School (UEA) defined , “Decentralised diabetes testing allows people to go to their GP or pharmacy and have these tests done there. This is important because it allows individuals to see their results immediately and therefore encourages them to achieve the target set out for them. It also enables the healthcare provider to be reassured that the level of improvement or control is a true representation of the metabolic situation.” He continued, “Basic laboratory support for clinical colleagues providing healthcare is fundamental; anything that allows our clinical teams to gather the complete information they need on the patient they are dealing with at that point in time is central to good metabolic control.”
Johannes Pachler , Managing Director of Leupamed Medizintechnik GmbH, a number one medical tools provider in Austria commented, “The HbA1c test is a welcome addition to the LumiraDx Platform for our customers, which includes more than 100 LumiraDx Platforms used by GPs and internal medicine groups. We know there is tremendous value for clinicians being able to share immediate results with patients – this is particularly true for the monitoring and screening of diabetes. The intuitive nature of the Platform and the accurate results of the HbA1c test make it an important tool for diabetes management and clinicians are already seeing the positive impact the test can make on patient care. “
About LumiraDx
LumiraDx Limited (Nasdaq: LMDX) is a next-generation level of care diagnostics firm that’s remodeling community-based healthcare. Its actively managed microfluidic expertise supplies quick, excessive efficiency and accessible diagnostic options wherever the affected person is for almost any testing state of affairs, creating distinctive testing choices on the level of want.
The firm presents a broad menu of lab comparable assessments on a single moveable Platform, with greater than 30 assays available on the market and within the pipeline, masking infectious ailments, cardiovascular ailments, diabetes, and coagulation issues. The firm additionally helps high-complexity laboratory testing in an accessible high-throughput format to leverage present molecular laboratory operations.
Founded in 2014 and based mostly within the UK, LumiraDx’s diagnostic testing options are being deployed globally by governments and main healthcare establishments throughout laboratories, pressing care, doctor workplaces, pharmacies, faculties, and workplaces to assist display, diagnose, and monitor wellness in addition to illness.
More info on LumiraDx is offered at www.lumiradx.com.
References:
1: worlddiabetesday.org/about/facts-figures/
2: diabetesjournals.org/care/article/22/11/1785/19794/Immediate-feedback-of-HbA1c-levels-improves
3. www.ncbi.nlm.nih.gov/pmc/articles/PMC4933534/
View authentic content material:https://www.prnewswire.co.uk/news-releases/lumiradx-continues-commercial-expansion-of-its-rapid-microfluidic-immunoassay-hba1c-test-301677062.html
